Science Corporation’s vision-restoring chip wins EU approval
The PRIMA chip offers hope for those with age-related macular degeneration.
1A solution for vision loss
Science Corporation has developed the PRIMA chip, designed to restore vision for those suffering from age-related macular degeneration. The chip, implanted at the back of the eye, allows patients to regain functional vision. Approved by the EU's medical device regulator, it has the potential to transform millions of lives.
2The mind behind the technology
Science Corp.'s founder and CEO, Max Hodak, was previously a co-founder of Neuralink. In 2021, he left to establish Science Corp., focusing on a novel brain-computer interface combining silicon chips and living cells. The company's first goal was to build a sustainable business model and bring PRIMA to market.
3How PRIMA works
The PRIMA chip is implanted at the back of the patient's eye. Camera-equipped glasses transmit images of the world to the chip, which processes them into signals the brain can interpret. This enables patients to read again and recognize faces, significantly improving their quality of life.
4Patient experiences
Patients using the PRIMA chip have shared inspiring stories. One in France finished a 300-page novel, while another sketched the Sydney Opera House. These successes highlight the technology's potential to restore not just vision but also independence and joy in daily activities.
5Commercial steps
The PRIMA chip is expected to cost hundreds of thousands of dollars. Science Corp. is in reimbursement discussions with healthcare providers in Europe, with the first procedures planned for Germany in September. The company is also working on advanced versions to further enhance vision capabilities.
6Future vision
Beyond PRIMA, Science Corp. is developing a directly implantable bio-hybrid brain sensor. However, the immediate priority is ensuring PRIMA's success. Hodak emphasizes that without a sustainable vision business, long-term bio-hybrid projects cannot proceed. PRIMA is the key product that will fund the company's ambitious future.